2025-11-23 - Analysis Report
Okay, here's a report based on the provided information, focusing on TMDX (TransMedics Group Inc.), with a mix of numbers and analysis.

**Report on TMDX (TransMedics Group Inc.)**

**Company Overview:** TransMedics Group Inc. is a medical technology company focused on developing and delivering innovative organ care system (OCS) solutions for end-stage organ failure patients.

**1. Performance vs. S&P 500 (VOO)**

*   **TMDX Cumulative Return:** 225.14%
*   **VOO Cumulative Return:** 70.06%
*   **Absolute Deviation (TMDX - VOO):** 155.08%
*   **Deviation Range (Max: 247.1, Min: -74.6, Current: 111.7, Relative Deviation: 57.9)**

**Analysis:** TMDX has significantly outperformed the S&P 500 (VOO) over the period examined, with a cumulative return difference of 155.08%. The Relative Deviation of 57.9 suggests that the current performance difference is positioned in the upper-middle range of its historical deviation from VOO.

**Alpha, Beta Analysis**

| Year       | CAGR    | MDD     | Alpha   | Beta  | Cap(B) |
| ---------- | ------- | ------- | ------- | ----- | ------ |
| 2019-2021  | -18.0%  | 83.5%  | -61.0%  | -0.0  | 0.7    |
| 2020-2022  | 94.0%  | 83.5%  | 95.0%  | 0.0   | 2.1    |
| 2021-2023  | 65.0%  | 80.5%  | 64.0%  | 0.1   | 2.7    |
| 2022-2024  | 130.0% | 85.5%  | 109.0% | 0.1   | 2.1    |
| 2023-2025  | 146.0% | 85.5%  | 87.0%  | 0.3   | 4.5    |

**Analysis:**

*   **CAGR:** TMDX has demonstrated strong compound annual growth rates (CAGR) in recent periods (2020-2025). However, the period from 2019-2021 shows a negative CAGR.
*   **MDD:** The Maximum Drawdown (MDD) is high, indicating significant volatility and potential risk.
*   **Alpha:** Alpha values are largely positive, indicating that TMDX has generated returns above what would be expected based on its beta and the market return.
*   **Beta:** Beta values are relatively low, suggesting that TMDX's price is not highly sensitive to movements in the S&P 500.
*   **Cap(B):** Market Cap is growing.

**2. Recent Price Action**

*   **Current Price:** 130.93
*   **Previous Close:** 123.82
*   **Change:** 5.74 (Significant jump)
*   **5-Day Moving Average:** 123.74
*   **20-Day Moving Average:** 125.12
*   **60-Day Moving Average:** 118.34

**Analysis:** The stock price has seen a significant increase of 5.74 from the previous close. The current price is above all three moving averages (5, 20, and 60-day), suggesting a short-term upward trend. The large 'change' value indicates a potential catalyst driving the price movement.

**3. Market Risk Indicators & Expected Return**

*   **Market Risk Indicator (MRI):** 0.8 (Medium Investment)
*   **RSI:** 55.12 (Neutral)
*   **PPO:** 0.32 (Slightly Bullish)
*   **Hybrid Signal:** Buy 100% of cash (8 shares - Very Safe - MRI:0.90). Monthly invest 1.2% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-11-03)
*   **20-Day Relative Deviation Change:** -3.3 (Short-term Decrease)
*   **Expected Return:** 57.9% (Long-Term vs. S&P 500)

**Analysis:**

*   The MRI suggests a medium level of investment risk.
*   The RSI is neutral, indicating neither overbought nor oversold conditions.
*   The PPO is slightly positive, suggesting a mild bullish trend.
*   The recent decrease in relative deviation suggests some short-term underperformance relative to the S&P 500.
*   The Expected Return is very high, implying significant potential outperformance over the S&P 500 in the long term, assuming a consistent investment strategy.
*   The significant price increase from the previous close should be considered when interpreting the Hybrid Signal. The algorithm might need to re-evaluate its recommendation based on the new price level.

**4. Recent News & Significant Events**

*   **Moving Average Crossovers:** Multiple articles highlight TMDX crossing above its 20-day and 50-day moving averages, often seen as bullish signals.
*   **Valuation:** Several articles suggest TMDX may be undervalued.
*   **Growth Stock:** TMDX is identified as a top-ranked growth stock.
*   **Conference Participation:** TransMedics participated in the Piper Sandler Healthcare Conference.

**Analysis:** The news is generally positive. The moving average crossovers, potential undervaluation, and recognition as a growth stock are all positive indicators. The conference participation suggests active engagement with the investment community.

**4-2. Analyst Opinions**

*   **Consensus:** Buy (~1.67 on a 1-5 scale)
*   **Opinions:** 11
*   **Target Price (Avg/High/Low):** $141.91 / $170.00 / $114.00
*   **Recent Rating Changes:** No recent rating changes

**Analysis:** The analyst consensus is strongly positive, with a "Buy" recommendation and a target price significantly above the current price, suggesting further upside potential.

**5. Overall Summary & Conclusion**

TMDX has demonstrated strong historical outperformance compared to the S&P 500, although with significant volatility as reflected in the high MDD values. Recent price action indicates a strong upward movement, supported by bullish moving average crossovers and positive news sentiment related to potential undervaluation and growth prospects. Analyst consensus is also strongly positive, with a significant upside target price.

**Recommendation:**

Based on this information, TMDX appears to be a potentially attractive investment opportunity, particularly for investors with a long-term perspective and a tolerance for volatility. The positive analyst ratings and the company's participation in industry conferences further support a bullish outlook. However, investors should be aware of the high MDD and the potential for short-term underperformance, as indicated by the recent decrease in relative deviation. The recent surge in price should be carefully considered, and it would be wise to monitor the stock's performance in the coming days to confirm the sustainability of the upward trend. It's crucial to conduct thorough due diligence and consider individual risk tolerance before making any investment decisions.
